Lerdelimumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TGF beta 2 |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.
It was being developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.[2]
References
- ^ "Lerdelimumab". Drugs in R&D. 3 (2): 106–8. 1 February 2002. doi:10.2165/00126839-200203020-00006. PMID 12001808.
- ^ "CAT abandons Trabio after second clinical trial failure". The Pharma Letter. 28 March 2005.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Monoclonal antibodies
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs